Loading organizations...
Loading organizations...
Element Science is a technology company.
Element Science develops the Jewel® Patch Wearable Cardioverter Defibrillator, a digital health solution providing continuous protection against life-threatening cardiac rhythms. Designed for high-risk cardiovascular patients, this wearable medical device integrates sophisticated machine learning with rigorous standards. Its human-centric engineering delivers a comfortable, effective platform.
Uday Kumar, MD, founded Element Science in 2011, inspired by innovative medical technology's profound impact. As a cardiac electrophysiologist and founder of iRhythm Technologies, Dr. Kumar brought significant expertise. His vision addressed the critical need to reduce cardiac mortality and improve patient outcomes.
The company's products serve high-risk cardiovascular patients susceptible to sudden cardiac arrest. Element Science's long-term vision aims to deliver a future free from this threat, enhancing patient peace of mind. They are committed to saving lives by creating solutions that empower individuals and reduce cardiac-related hospitalizations.
Element Science has raised $150.0M across 1 funding round.
Element Science has raised $150.0M in total across 1 funding round.
Element Science has raised $150.0M in total across 1 funding round.
Element Science's investors include Deerfield Management, Christopher Shen, Cormorant Asset Management, Google Ventures, Invus Opportunities, Neil Exter.
Element Science is a medical device and digital health company developing wearable solutions to prevent sudden cardiac arrest, primarily targeting patients transitioning from hospital to home with heart disease risks.[1][2] Its flagship product, the Jewel wearable cardioverter defibrillator (also called Jewel Patch), is a user-friendly, patch-style device that provides continuous cardiac monitoring and lifesaving therapy using data science and machine learning.[1][2][4] The company serves high-risk patients (over 500,000 annually in the US) and healthcare providers, solving the problem of undetected lethal heart rhythms during vulnerable post-hospital periods by offering comfortable, personalized wearables that prioritize patient and physician needs.[2]
Founded in 2011 and based in San Francisco, Element Science has achieved regulatory milestones like CE Mark and UKCA Mark approvals for Jewel, signaling growth momentum toward commercialization in Europe and beyond, with backing from prominent investors including Third Rock Ventures, Google Ventures, and Deerfield Management.[1][2]
Element Science was founded in 2011 in San Francisco, California, originally as Revive Defibrillation Systems, before rebranding to focus on its mission.[1] The company's inception stemmed from recognizing gaps in cardiac care for patients at temporary elevated risk of sudden cardiac arrest post-hospitalization, driving the development of innovative wearables at the nexus of clinical-grade hardware, machine learning, and therapies.[2][3] Key early traction includes the evolution of the Jewel Patch-Wearable Cardioverter Defibrillator, with pivotal regulatory wins like the 2023 CE Mark and UKCA Mark, enabling market entry and validating its patient-centered approach.[2] While specific founder details are not detailed in available sources, the team's expertise in medical devices and digital health has propelled it from concept to a funded entity with approximately 75 employees and $9.8 million in revenue.[2]
Element Science stands out in the wearable cardiac health space through these key strengths:
Element Science rides the wave of wearable health tech and remote patient monitoring, accelerated by post-COVID demands for hospital-at-home solutions and AI-driven diagnostics in cardiology.[1][2] Timing is ideal amid rising chronic heart disease prevalence and a market favoring non-invasive, data-powered devices over legacy equipment, with favorable forces like regulatory streamlining for digital therapeutics and investor interest in medtech (evidenced by its blue-chip funding).[2] It influences the ecosystem by redefining defibrillator paradigms—shifting from cumbersome vests to patches—potentially lowering barriers to adoption for the 500,000+ US patients at risk annually, while competing with players like VitalConnect in biosensor tech and fostering innovation in neurology-cardiology crossovers.[1][2]
Element Science is poised for expansion with Jewel's regulatory approvals paving the way for US FDA clearance and global launches, potentially capturing significant share in the wearable defibrillator market.[2][4] Trends like AI-enhanced wearables, value-based care, and aging populations will propel growth, with opportunities in clinical trials and chronic disease management. Its influence may evolve from niche innovator to category leader, transforming cardiac care accessibility—building directly on its mission to deliver lifesaving tech that feels like an everyday essential.[1][2][4]
Element Science has raised $150.0M across 1 funding round. Most recently, it raised $150.0M Series C in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $150.0M Series C | Deerfield Management, Christopher Shen | Cormorant Asset Management, Google Ventures, Invus Opportunities, Neil Exter |